Molly C

Global PR pro focused on #CancerDiagnostics, #biotech, health & #technology; work @Veracyte; Fan of fitness, travel, food, sports, @Cardinals & music!

[Molly C @Mollify]

@Breastcancerorg @IR_Macpherson

[Breastcancer.org @Breastcancerorg]

Listen to Iain MacPherson, MD, PhD, professor of breast oncology, on our latest podcast episode discuss the OPTIMA trial and how a low Prosigna Risk of Recurrence score may help some people with early-stage HR-positive, HER2-negative breast cancer safely avoid chemotherapy, as well as how he thinks these findings could shape future treatment decisions.
🎧https://t.co/fkdlzMyv83

[Veracyte, Inc. @Veracyte]

We are proud to announce the U.S. commercial launch of the Prosigna® Breast Risk of Recurrence (ROR) test, a genomic test for patients diagnosed with early-stage hormone-receptor positive (HR+) breast cancer. The #ProsignaBreastTest will be available to order starting June 8, 2026.

| Impact |

On the heels of the landmark #OPTIMA trial readout at #ASCO26, the Prosigna test now offers clinicians and the patients they serve not only a deeper understanding of individual risk of recurrence, but for many, whether chemotherapy can benefit them or whether they may safely avoid it.

In the U.S., more than 225,000 new HR+/HER2- breast cancer cases are diagnosed each year. When breast cancer is diagnosed early and treated appropriately, five-year survival rates reach 92%(1). It is critically important to accurately determine a patient's risk of recurrence because the effects of treatment escalation or de-escalation have a lasting impact on a patient's life.

| Why the Prosigna Test Stands Apart |

🔹 Comprehensive molecular analysis: The Prosigna test was developed from the PAM50 genomic classifier and is the only test that combines intrinsic subtypes and proliferation score with clinical pathological factors to provide a comprehensive 10-year probability of distant recurrence.

🔹 Proven across high-risk populations: Based on the phase III, prospective, OPTIMA trial, the Prosigna test is the only test proven to be predictive for chemotherapy benefit for high-clinical risk patients with up to 9 positive nodes, including premenopausal women treated with ovarian function suppression.

🔹 Superior prognostic accuracy: Extensively validated clinical evidence demonstrates that the Prosigna test is more prognostically accurate than other genomic assays, particularly in the critical 5-10 year breast cancer recurrence window.

| Access and Availability |

The Prosigna test will be available to order starting June 8, 2026 through Veracyte's network nationwide via the Veracyte Ordering Portal. The test is currently covered by most commercial payers, and patients may qualify for financial assistance or a tailored payment plan supported by the Veracyte Access Program for eligible uninsured and underinsured patients.

| Resources |

📄 Read the full press release - https://t.co/B8LeuqFGKd

🔗 Prosigna clinical resources - https://t.co/vGSwkG60Z9

🔗 Veracyte ordering portal for providers - https://t.co/tdzUPwYmwK

#BreastCancer #PrecisionMedicine #CancerDiagnostics

| References |

(1) National Breast Cancer Foundation, Inc., Breast Cancer Facts & Stats; Last updated Apr 20, 2026. https://t.co/ZmPKXGmCFp

Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit: https://t.co/fQcKkGFugi

[Kristie Lu Stout✌🏽 @klustout]

Fifty years ago, on May 16, 1975, Junko Tabei escaped an avalanche and became the first woman to summit Everest.

She is also the first woman to complete the “Seven Summits,” climbing the highest peaks on every continent.

Let's remember her name.

https://t.co/0Mg2V0x5IT

[Molly C @Mollify]

A great advancement in #cancercare and #precisionmedicine. This is why I do the work I do every day. #nextgenerationsequencing #oncology #cancer #AML #myeloMATCH #NIH #NCI

[GenomeWeb @GenomeWeb]

Thermo Fisher, NCI Partner for Myeloid Cancer Precision Medicine Umbrella Trial https://t.co/x3JBFcbXVD

[Christina Farr @chrissyfarr]

New on Second Opinion:

An opinion column arguing that storytelling should be a core part of medical curriculum, *especially* in the era of AI. Link in bio! With @drRohanR

[Molly C @Mollify]

@amazon a lot of people got charged incorrectly for Prime Day items. Are you resolving this? #PrimeDay

[Amazon @amazon]

Tingling with excitement for July 11-12! #primeday

[Molly C @Mollify]

Great news for so many women impacted by #preeclampsia. Innovations like these from @thermofisher can be life-saving. #MyCompany #Biotech #BreakthroughInnovations

[Reuters Health @Reuters_Health]

The U.S. Food and Drug Administration (FDA) has cleared Thermo Fisher Scientific Inc's test, the first of its kind in the country, to detect women with risk of severe preeclampsia, the company said on Friday. https://t.co/unx58NozE3

[Molly C @Mollify]

Important topic for how we can help more people with cell and gene therapy treatment. @thermofisher is playing a critical role in enabling this with customers. #biotech #cellandgenetherapy #MyCompany

[Genetic Engineering & Biotechnology News @GENbio]

Decentralizing the Manufacturing of Cell and Gene Therapies. Read more: https://t.co/4EZFtgRphH

[Thermo Fisher @thermofisher]

We're proud to support & celebrate future #STEM leaders with @Society4Science! Last week, colleagues from our Austin site volunteered at the @AustinEnergy Regional Science Festival. The top performers are eligible to apply for the Thermo Fisher #JuniorInnovators ChallengeWe're proud to support & celebrate future #STEM leaders with @Society4Science! Last week, colleagues from our Austin site volunteered at the @AustinEnergy Regional Science Festival. The top performers are eligible to apply for the Thermo Fisher #JuniorInnovators ChallengeWe're proud to support & celebrate future #STEM leaders with @Society4Science! Last week, colleagues from our Austin site volunteered at the @AustinEnergy Regional Science Festival. The top performers are eligible to apply for the Thermo Fisher #JuniorInnovators ChallengeWe're proud to support & celebrate future #STEM leaders with @Society4Science! Last week, colleagues from our Austin site volunteered at the @AustinEnergy Regional Science Festival. The top performers are eligible to apply for the Thermo Fisher #JuniorInnovators Challenge!

[Molly C @Mollify]

@sdcwa How do I get an application to pay my bill for a new house? I keep getting notices and cannot get through to anyone via phone or email.

[Molly C @Mollify]

In honor of @TeriGoudie, sharing this article with a great summary of her best communications training tips. You were a legend and the best-best-of-the-best, Teri, and we will all miss you a lot. Thanks for teaching us all to be better storytellers. RIP.

https://t.co/H23YwLDeHy

[Molly C @Mollify]

THIS!

[Amanda Gorman @TheAmandaGorman]

Pregnancy is a private and personal decision.
It should never require the permission of any politician.

[Molly C @Mollify]

This is what it’s all about, thank you @DICKS, @LEVIS and all the companies speaking out today for women!!

[Molly C @Mollify]

I support companies and brands speaking out to today’s news.

[Levi Strauss & Co. @LeviStraussCo]

With today’s Supreme Court ruling, we want to reiterate our commitment to supporting reproductive rights. https://t.co/w696cN9Fc9

[Amanda Gorman @TheAmandaGorman]

It takes a monster to kill children. But to watch monsters kill children again and again and do nothing isn’t just insanity—it’s inhumanity.

[Molly C @Mollify]

This is amazing! My favorite all-time @MLB player pitching when @Cardinals are up 18-0 in game this weekend! #Yadi #StlouisCardinals #MLB

[St. Louis Cardinals @Cardinals]

Now pitching, number 4, Yadier Molina!

[Molly C @Mollify]

Great to be a part of this exciting ceremony for @thermofisher’s new Ogden site that’s making a lifesaving impact around the globe. #MyCompany #Biotech #HealthTech #Bioprocessing

[Thermo Fisher @thermofisher]

See the highlights from the ribbon-cutting ceremony at our new #bioproduction facility in Ogden, Utah. The celebration included hundreds of employees and company leaders along with local officials @SenatorRomney @SenMikeLee @RepBlakeMoore. https://t.co/WBMXnMrjc2

[Molly C @Mollify]

Great event today to celebrate the opening of @thermofisher’s Ogden, UT bioprocessing site, which will enable vaccines and therapies for millions of people. #MyCompany #Biotech #Health

[ABC4 News @abc4utah]

Both Senator Mitt Romney and Senator Mike Lee attended the opening of a new biotech facility in Ogden

https://t.co/2qSlidcdc8

[Molly C @Mollify]

The expansion of this @thermofisher site will enable the commercialization of more life-saving therapies and vaccines. #bioprocessing #science #jobs

[FiercePharma @FiercePharma]

Thermo Fisher, plowing ahead on a $650 million bioprocessing expansion, has unveiled a $40 million upgrade at its single-use technologies facility in Millersburg, Pennsylvania. https://t.co/C8lXrt005R